Shilpa Medicare shares jumped more than 2% in morning trade after its subsidiary Shilpa Pharma Lifesciences Limited received a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin.
Shilpa Pharma Lifesciences manufactures desmopressin, a synthetic peptide that is used to treat central diabetic insipidus and bedwetting. This CEP demonstrates Shilpa’s dedication to quality-driven development and commercial manufacturing capabilities.
As of 10:19 am, Shilpa Medicare shares were trading 2.39% higher at Rs 824.95 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
